BCLI | tickerfilter.com

Fundamental analysis

23%

Profitability 25%

Dept financing 23%

Liquidity 43%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.19%

1 Month

57.04%

3 Months

813.56%

6 Months

471.79%

1 Year

1,028.54%

2 Year

49.66%

Key data

Stock price

$2.35

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$0.25 - $3.71

52 WEEK CHANGE

$679.72

MARKET CAP

24.638 M

YIELD

N/A

SHARES OUTSTANDING

79.734 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/12/2024

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$180,700

AVERAGE 30 VOLUME

$127,254

Company detail

CEO: Chaim Lebovits
Region: US
Website: brainstorm-cell.com
Employees: 40
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Brainstorm Cell Therapeutics Inc. engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. It is developing NurOwn, which has completed Phase III clinical trial for the. treatment of amyotrophic lateral sclerosis; and Phase II clinical trial. for. progressive multiple sclerosis and alzheimer's disease. The company was formerly known as Golden Hand Resources Inc.

BCLI - BRAINSTORM CELL THERAPEUTICS INC.